Tenaya Therapeutics, Inc.
30.30%
49,313,559
1858848
87990A106
May 6, 2025
May 14, 2025, 04:18 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| The Column Group Opportunity III, LP | Partnership | 30.30% | 49,313,559 | 0 | 49,313,559 |
| The Column Group Opportunity III GP, LP | Partnership | 30.30% | 49,313,559 | 0 | 49,313,559 |
| TCG Opportunity III GP, LLC | Other | 30.30% | 49,313,559 | 0 | 49,313,559 |
| The Column Group III GP, LP | Partnership | 5.80% | 9,400,290 | 0 | 9,400,290 |
| The Column Group III-A, LP | Partnership | 3.10% | 4,985,570 | 0 | 4,985,570 |
| The Column Group III, LP | Partnership | 2.70% | 4,414,720 | 0 | 4,414,720 |
Disclosure Items (6)
Common Stock, par value $0.0001 per share
Tenaya Therapeutics, Inc.
171 Oyster Point Boulevard, South San Francisco, CA, 94080
The information set forth in Item 2(a) of the Original Schedule 13D is incorporated herein by reference.
The information set forth in Item 2(b) of the Original Schedule 13D is incorporated herein by reference.
The information set forth in Item 2(c) of the Original Schedule 13D is incorporated herein by reference.
The information set forth in Item 2(e) of the Original Schedule 13D is incorporated herein by reference.
The information set forth in Item 2(f) of the Original Schedule 13D is incorporated herein by reference.
The information set forth in Item 3 of the Original Schedule 13D is incorporated herein by reference.
See Items 7-11 of the cover pages of this Amendment No. 4.
See Items 7-11 of the cover pages of this Amendment No. 4.
Except as reported in this Statement, none of the Reporting Persons has affected any transactions in the Issuer's securities within the past 60 days.
Under certain circumstances set forth in the limited partnership agreements of each of TCG III LP, TCG III-A LP and TCG Opportunity III LP, the general partner and limited partners of TCG III LP, TCG III-A LP and TCG Opportunity III LP, as applicable, may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.
Not applicable.
The information set forth in Item 6 of the Original Schedule 13D is incorporated herein by reference.